Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

EVOK Stock - Evoke Pharma Stock Trading


home / stock / evok

EVOK EVOK Quote EVOK Short EVOK News EVOK Articles EVOK Message Board

MWN AI Summary *

Evoke Pharma Inc. (NASDAQ: EVOK) is a biopharmaceutical company focused on developing innovative therapeutic solutions for gastrointestinal diseases, with a particular emphasis on gastrointestinal motility disorders. The company is headquartered in San Diego, California, and primarily concentrates on its lead product candidate, Gimoti, which is a novel formulation of metoclopramide. Gimoti is designed to treat acute and recurrent nausea and vomiting in patients with gastroparesis, a condition where the stomach takes too long to empty its contents.

Evoke received FDA approval for Gimoti in December 2020, making it the first nasal spray formulation of metoclopramide specifically indicated for gastroparesis in diabetic patients. This approval was a significant milestone for the company, as it represents a potential breakthrough in a market that has limited treatment options. The nasal spray route allows for faster absorption and could offer a more convenient option for patients compared to traditional oral medications.

Despite these developments, Evoke has faced its share of challenges, notably in driving market adoption and generating sales, which can be common in the pharmaceutical sector following product launches. The company has been actively working on its commercialization strategy, including partnerships and marketing efforts, to increase awareness and utilization of Gimoti among healthcare providers and patients.

Investors have shown mixed sentiments towards EVOK shares, reflecting both the potential upside of its unique product offering and the inherent risks associated with biotech stocks, particularly in market penetration efforts and regulatory hurdles. As Evoke Pharma continues to navigate its post-approval journey, stakeholders will be keenly watching its sales performance and any future developments in its pipeline, which may influence the company’s trajectory in the competitive biopharmaceutical landscape.

MWN AI Analysis *

Evoke Pharma Inc. (NASDAQ: EVOK) is a biopharmaceutical company focused on developing and commercializing novel medicines for gastrointestinal diseases, notably its lead product, Gimoti, a nasal spray formulation of metoclopramide approved for the treatment of diabetic gastroparesis in women. As of October 2023, the stock has shown volatility, reflecting the inherent risks and opportunities in the biotech sector.

Investors should consider several factors when evaluating Evoke Pharma. The company is operating in a niche market with a specific therapeutic focus, which can limit its growth potential compared to larger pharmaceuticals. However, the approval of Gimoti represents a significant milestone, offering a unique delivery method that could appeal to patients unable to tolerate oral medications.

Financially, Evoke Pharma has faced challenges regarding revenue generation since drug launch, indicating the importance of execution in commercial strategy. Investors should closely monitor sales trends for Gimoti, as sustained growth will be essential for bolstering the company’s valuation. The company’s ability to expand its market share through effective marketing and physician outreach will be critical, as will ongoing assessments of pricing strategies and reimbursement negotiations with payers.

Additionally, it’s prudent to keep an eye on regulatory developments and competitor products in the space. The biotech sector is known for rapid changes, particularly with innovations promising better efficacy or patient experience. The potential for partnerships or collaborations with larger pharmaceutical firms could also provide further upside, leveraging Evoke’s innovative product while alleviating some of the financial pressures.

In conclusion, while Evoke Pharma Inc. offers a unique pharmaceutical product with promising potential, investors are advised to approach with caution. A thorough understanding of market dynamics, financial health, and strategic execution will be essential for making informed investment decisions in this volatile sector.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Evoke Pharma Inc. (NASDAQ:EVOK)

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Quote | Evoke Pharma Inc. (NASDAQ:EVOK)

Last:$6.99
Change Percent: -219.55%
Open:$8.5
Close:$6.99
High:$9.88
Low:$6.12
Volume:139,642,901
Last Trade Date Time:07/09/2025 03:40:44 pm

News | Evoke Pharma Inc. (NASDAQ:EVOK)

  • Stocks to Watch: Innovation, Expansion, and Breakout Biotech Catalysts

    2025-07-09 10:03:41 ET DENVER, Colo., Jul 09, 2025 ( 247marketnews.com )- Evoke Pharma (NASDAQ: EVOK) received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering the use of GIMOTI in treating patients with moderate to severe...

    • July 09, 2025 10:03:41 am

    • |
    • 24/7 Market News
    • |
      • EVOK Stock
      • EVOK Quote
      • EVOK Short
      • EVOK News
      • EVOK Articles
      • EVOK Message Board
  • Evoke Pharma Receives Notice from USPTO for GIMOTI Extending Orange Book Listings to 2036

    2025-07-09 09:16:49 ET DENVER, Colo., Jul 09, 2025 ( 247marketnews.com )- Evoke Pharma (NASDAQ:EVOK) received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering the use of GIMOTI in patients with moderate to severe symptoms of...

    • July 09, 2025 09:16:49 am

    • |
    • 24/7 Market News
    • |
      • EVOK Stock
      • EVOK Quote
      • EVOK Short
      • EVOK News
      • EVOK Articles
      • EVOK Message Board

Message Board Posts | Evoke Pharma Inc. (NASDAQ:EVOK)

Subject By Source When
whytestocks: $EVOK News Article - USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMO whytestocks investorshangout 12/07/2022 1:35:48 PM
whytestocks: $EVOK News Article - Evoke Pharma Recognizes Gastroparesis Awareness Month through its whytestocks investorshangout 08/01/2022 7:35:55 PM
znewcar1: ML2.75 MH3.49 flat and no vol znewcar1 investorshangout 07/21/2022 4:01:32 AM
whytestocks: $EVOK News Article - Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent whytestocks investorshangout 07/06/2022 2:55:53 PM
Same here with me! I never caught COVID subslover investorshub 06/16/2022 9:44:50 PM

MWN AI FAQ **

What recent developments or clinical trial results have impacted Evoke Pharma Inc. (NASDAQ: EVOK) and its future growth prospects?

Recent developments for Evoke Pharma Inc. (NASDAQ: EVOK) include the positive clinical trial results for their drug, Gimoti, which are expected to enhance growth prospects by increasing market acceptance and potential sales in treating acute diabetic gastroparesis.

How does Evoke Pharma Inc. EVOK's financial performance compare to its competitors in the gastrointestinal treatment market?

Evoke Pharma Inc. (EVOK) faces challenges in financial performance compared to its competitors in the gastrointestinal treatment market, struggling with lower revenue and market share amid the competitive landscape dominated by more established players.

What strategic partnerships or collaborations has Evoke Pharma Inc. (NASDAQ: EVOK) pursued to enhance its market position?

As of October 2023, Evoke Pharma Inc. has pursued strategic partnerships, including collaborations for marketing and distribution of its drug Gimoti for the treatment of gastroparesis, aiming to enhance its market presence and reach more patients.

How is Evoke Pharma Inc. EVOK addressing challenges in regulatory approvals and market penetration for its lead product?

Evoke Pharma Inc. (EVOK) is addressing regulatory challenges for its lead product by engaging with the FDA for guidance on clinical trial requirements and focusing on strategic partnerships to enhance market penetration and distribution channels.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get EVOK Alerts

News, Short Squeeze, Breakout and More Instantly...

Trending Stock

-219.55% Change Percent:

Evoke Pharma Inc. Company Name:

EVOK Stock Symbol:

NASDAQ Market:

-219.55% G/L:

$6.99 Last:

139,642,901 Volume:

$8.50 Open:

$6.99 Close:

Evoke Pharma Inc. Website:

Evoke Pharma Inc. Logo

Ad

Trending Stock Alerts
RECENT EVOK NEWS
  • EVOK - Stocks to Watch: Innovation, Expansion, and Breakout Biotech Catalysts

    2025-07-09 10:03:41 ET DENVER, Colo., Jul 09, 2025 ( 247marketnews.com )- Evoke Pharma (NASDAQ: EVOK) received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering the use of GIMOTI in treating patients with moderate to severe...

  • EVOK - Evoke Pharma Receives Notice from USPTO for GIMOTI Extending Orange Book Listings to 2036

    2025-07-09 09:16:49 ET DENVER, Colo., Jul 09, 2025 ( 247marketnews.com )- Evoke Pharma (NASDAQ:EVOK) received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering the use of GIMOTI in patients with moderate to severe symptoms of...

  • EVOK - Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

    SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received a No...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get EVOK Alerts

Get EVOK Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1